Endocrinology

Genitourinary Cancers

Questions discussed in this category

Do you use denosumab for castration-sensitive prostate cancer with osseous metastases?

Only the mCRPC population was included in the Fizazi et al. study, but the FDA approval is for prevention of skeletal related events from any solid tu...

4 Answers available

Are there any concerns regarding side effects in changing from denosumab to zolendronic acid or vice versa?

1 Answer available

Should bone-directed agents, such as denosumab or zoledronic acid, be given when patients are being treated with radium-223?

1 Answer available

Papers discussed in this category

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-04-10

Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).

Cancer Chemother Pharmacol, 2021 Mar 31

Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases.

J Bone Miner Metab, 2020 Jul 12

Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment.

Endocrinology

Genitourinary Cancers

Questions discussed in this category

Papers discussed in this category

Related Topics in Endocrinology